Kawasaki Disease

Pediatric Clinics of North America

Volumn 59, Issue 2, 2012, Pages 425-445

  Scuccimarri, Rosie ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Aneurysm; Coronary artery; Intravenous immunoglobulin; Kawasaki disease; Mucocutaneous lymph node syndrome; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PERCEPTION DEAFNESS; REVIEW; REYE SYNDROME; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHILD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MUCOCUTANEOUS LYMPH NODE SYNDROME; RISK FACTORS;

EID: 84860501790     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.03.009     Document Type: Review

References (139)

1. Taubert K.A., Rowley A.H., Shulman S.T. A nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991, 119:279-282.
2. Yanagawa H., Nakamura Y., Ojima T., et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J 1999, 18:64-66.
3. Kawasaki T. Arerugi (Jpn J Allergy) 1967, 16:178-222. [in Japanese].
4. Burns J.C., Kushner H.I., Bastian J.F., et al. Kawasaki disease: a brief history. Pediatrics 2000, 106(2):e27.
5. Yamamoto T., Kimura J. Shonika Rinsho (Jpn J Pediatr) 1968, 21:336-339. [in Japanese].
6. Shigematsu I. Nippon Shonika Gakkai Zasshi (J Jpn Pediatr Soc) 1972, 76:695-696. [in Japanese].
7. Melish M.E., Hicks R.M., Larson E.J. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child 1976, 130:599-607.
8. Nakamura Y., Yashiro M., Uehara R., et al. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol 2008, 18(4):167-172.
9. Nakamura Y., Yashiro M., Uehara R., et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010, 20(4):302-307.
10. Nakamura Y., Yanagawa H. The worldwide epidemiology of Kawasaki disease. Prog Pediatr Cardiol 2004, 19:99-108.
11. Lin Y.T., Manlhiot C., Ching J.C., et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int 2010, 52:699-706.
12. Park Y.W., Han J.W., Park I.S., et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J 2007, 26:821-823.
13. Huang W.C., Huang L.M., Chang I.S., et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009, 123:e401-e405.
14. Holman R.C., Belay E.D., Christensen K.Y., et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J 2010, 29:483-488.
15. Lynch M., Holman R.C., Mulligan A., et al. Kawasaki syndrome hospitalizations in Ireland, 1996 through 2000. Pediatr Infect Dis J 2003, 22:959-963.
16. Harnden A., Alves B., Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002, 324:1424-1425.
17. Heaton P., Wilson N., Nicholson R., et al. Kawasaki disease in New Zealand. J Paediatr Child Health 2006, 42:184-190.
18. Royle J.A., Williams K., Elliott E., et al. Kawasaki disease in Australia, 1993-95. Arch Dis Child 1998, 78:33-39.
19. Yeung R.S. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010, 22:551-560.
20. Newburger J.W., Takahashi M., Gerber M.A., et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 2004, 110:2747-2771.
21. Holman R.C., Curns A.T., Belay E.D., et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J 2005, 24:429-433.
22. Uehara R., Yashiro M., Nakamura Y., et al. Kawasaki disease in parents and children. Acta Paediatr 2003, 92:694-697.
23. Leung D.Y., Giorno R.C., Kazemi L.V., et al. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995, 155(10):5018-5021.
24. Rowley A.H., Shulman S.T. Recent advances in the understanding and management of Kawasaki disease. Curr Infect Dis Rep 2010, 12(2):96-102.
25. Rowley A.H., Eckerley C.A., Jack H.M., et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997, 159(12):5946-5955.
26. Rowley A.H., Baker S.C., Orenstein J.M., et al. Searching for the cause of Kawasaki disease-cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008, 6(5):394-401.
27. Onouchi Y., Gunji T., Burns J.C., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008, 40(1):35-42.
28. Burgner D., Davila S., Breunis W.B., et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009, 5(1):e1000319.
29. Khor C.C., Davila S., Shimizu C., et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet 2011, 48(7):467-472.
30. Kim J.J., Hong Y.M., Sohn S., et al. A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet 2011, 129(5):487-495.
31. Shrestha S., Wiener H.W., Olson A.K., et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol 2011, 128(3):677-680.
32. Lang B. Recognizing Kawasaki disease. Paediatr Child Health 2001, 6(9):638-643.
33. Benseler S.M., McCrindle B.W., Silverman E.D., et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005, 116(6):e760-e766.
34. Jordan-Villegas A., Chang M.L., Ramilo O., et al. Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J 2010, 29(8):770-772.
35. Friter B.S., Lucky A.W. The perineal eruption of Kawasaki syndrome. Arch Dermatol 1988, 124(12):1805-1810.
36. Wang S., Best B.M., Burns J.C. Periungual desquamation in patients with Kawasaki disease. Pediatr Infect Dis J 2009, 28(6):538-539.
37. Berard R., Scuccimarri R., Chédeville G. Leukonychia striata in Kawasaki disease. J Pediatr 2008, 152(6):889.
38. Yoskovitch A., Tewfik T.L., Duffy C.M., et al. Head and neck manifestations of Kawasaki disease. Int J Pediatr Otorhinolaryngol 2000, 52(2):123-129.
39. Ohno S., Miyajima T., Higuchi M., et al. Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982, 93:713-717.
40. Burns J.C., Joffe L., Sargent R.A., et al. Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis 1985, 4(3):258-261.
41. Gong G.W., McCrindle B.W., Ching J.C., et al. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006, 148(6):800-805.
42. Baker A.L., Lu M., Minich L.L., et al. Associated symptoms in the ten days prior to diagnosis of Kawasaki disease. J Pediatr 2009, 154(4):592-595.
43. Suddleson E.A., Reid B., Woolley M.M., et al. Hydrops of the gallbladder associated with Kawasaki syndrome. J Pediatr Surg 1987, 22(10):956-959.
44. Wright H., Waddington C., Geddes J., et al. Facial nerve palsy complicating Kawasaki disease. Pediatrics 2008, 122(3):e783-e785.
45. Sundel R.P., Cleveland S.S., Beiser A.S., et al. Audiologic profiles of children with Kawasaki disease. Am J Otol 1992, 13(6):512-515.
46. Knott P.D., Orloff L.A., Harris J.P., et al. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol 2001, 22(5):343-348.
47. Magalhães C.M., Mãgalhaes Alves N.R., Oliveira K.M., et al. Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol 2010, 16(7):322-325.
48. Kuniyuki S., Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol 1997, 37(2 Pt 2):303-304.
49. Bertotto A., Spinozzi F., Vagliasindi C., et al. Tuberculin skin test reactivity in Kawasaki disease. Pediatr Res 1997, 41(4 Pt 1):560-562.
50. Eberhard B.A., Sundel R.P., Newburger J.W., et al. Psoriatic eruption in Kawasaki disease. J Pediatr 2000, 137(4):578-580.
51. Tomita S., Chung K., Mas M., et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992, 14(1):121-126.
52. Muise A., Tallett S.E., Silverman E.D. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome?. Pediatrics 2003, 112:e495-e497.
53. Latino G.A., Manlhiot C., Yeung R.S., et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010, 32(7):527-531.
54. Rowe P.C., Quinlan A., Luke B.K. Value of degenerative change in neutrophils as a diagnostic test for Kawasaki syndrome. J Pediatr 1991, 119:370-374.
55. Birdi N., Klassen T.P., Quinlan A., et al. Role of the toxic neutrophil count in the early diagnosis of Kawasaki disease. J Rheumatol 1999, 26:904-908.
56. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991, 33(6):805-810.
57. Dahdah N., Siles A., Fournier A., et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009, 30(6):810-817.
58. Sato Y.Z., Molkara D.P., Daniels L.B., et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 2011, [Epub ahead of print].
59. Kaneko K., Yoshimura K., Ohashi A., et al. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 2011, 32(8):1106-1109.
60. Kato H. Cardiovascular involvement in Kawasaki disease: evaluation and natural history. Prog Clin Biol Res 1987, 250:277-286.
61. Akagi T., Kato H., Inoue H.K., et al. Valvular heart disease in Kawasaki syndrome-incidence and natural history. Kurume Med J 1989, 36(3):137-149.
62. Fujiwara H., Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978, 61:100-107.
63. Kanegaye J.T., Wilder M.S., Molkara D., et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009, 123(5):e783-e789.
64. Dajani A.S., Taubert K.A., Gerber M.A., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87(5):1776-1780.
65. Capannari T.E., Daniels S.R., Meyer R.A., et al. Sensitivity, specificity and predictive value of two-dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease. J Am Coll Cardiol 1986, 7(2):355-360.
66. Foster B.J., Bernard C., Drummond K.N. Kawasaki disease complicated by renal artery stenosis. Arch Dis Child 2000, 83(3):253-255.
67. Newburger J.W. Kawasaki disease: who is at risk?. J Pediatr 2000, 137(2):149-152.
68. Sonobe T., Kiyosawa N., Tsuchiya K., et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007, 49(4):421-426.
69. Manlhiot C., Yeung R.S., Clarizia N.A., et al. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009, 124(3):e410-e415.
70. Chang F.Y., Hwang B., Chen S.J., et al. Characteristics of Kawasaki disease in infants younger than 6 months of age. Pediatr Infect Dis J 2006, 25(3):241-244.
71. Momenah T., Sanatani S., Potts J., et al. Kawasaki disease in the older child. Pediatrics 1998, 102(1):e7.
72. Kawasaki T., Kosaki F., Okawa S., et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MCLS) prevailing in Japan. Pediatrics 1974, 54:271-276.
73. Furusho K., Nakano H., Shinomiya K., et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984, 2:1055-1058.
74. Newburger J.W., Takahashi M., Burns J.C., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315:341-347.
75. Newburger J.W., Takahashi M., Beiser A.S., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
76. Wolf H.M., Eibl M.M. Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol 1996, 14(Suppl 15):S17-S25.
77. Orbach H., Katz U., Sherer Y., et al. Intravenous immunoglobulins: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29(3):173-184.
78. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007, 38(1-3):122-132.
79. Gordon D.J., Sloan S.R., de Jong J.L. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol 2009, 84:771-772.
80. Berard R, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases [abstract p182]. Programs and abstracts of the ninth international Kawasaki disease symposium. Taipei (Taiwan); 2008. p. 92. Available at: . Accessed March 6, 2012. http://www.tspc.org.tw/IX_IKDS_Abstracts/Abstracts.pdf.
81. Oates-Whitehead R.M., Baumer J.H., Haines L., et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003, 4. CD004000.
82. Lang B., Duffy C.M. Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 2002, 16(3):427-442.
83. Akagi T., Kato H., Inoue O., et al. A study on the optimal dose of aspirin therapy in Kawasaki disease-clinical evaluation and arachidonic acid metabolism. Kurume Med J 1989, 37:203-208.
84. Kato H., Koike S., Tanaka C., et al. Coronary heart disease in children with Kawasaki disease. Jpn Circ J 1979, 43:469-475.
85. Akagi T., Kato H., Inoue O., et al. Salicylate treatment in Kawasaki disease: high dose or low dose?. Eur J Pediatr 1991, 150(9):642-646.
86. Newburger J.W. Treatment of Kawasaki disease. Lancet 1996, 347:1128.
87. Koren G., MacLeod S.M. Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease. J Pediatr 1984, 105(6):991-995.
88. Hanley S.P., Bevan J., Cockbill S.R., et al. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981, 1:969-971.
89. Wei C.M., Chen H.L., Lee P.I., et al. Reye's syndrome developing in an infant on treatment of Kawasaki syndrome. J Paediatr Child Health 2005, 41:303-304.
90. Matsubara T., Mason W., Kashani I.A., et al. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996, 128(5 Pt 1):701-703.
91. Melish M.E., Takahashi M., Shulman S.T., et al. Comparison of low dose aspirin (LDA) vs high dose aspirin (HDA) as an adjunct to intravenous gamma globulin (IVIG) in the treatment of Kawasaki syndrome (KS). Pediatr Res 1992, 31:170A.
92. Scuccimarri R., Rohlicek C., Watanabe Duffy K.N., et al. Incidence of early cardiac abnormalities in children with Kawasaki disease treated with low dose aspirin and intravenous immunoglobulin in the acute phase. Arthritis Rheum 2001, 44(9):S169. [abstract 700].
93. Hsieh K.S., Weng K.P., Lin C.C., et al. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004, 114(6):e689-e693.
94. Terai M., Shulman S.T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997, 131(6):888-893.
95. Durongpisitkul K., Gururaj V.J., Park J.M., et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96(6):1057-1061.
96. Baumer J.H., Love S.J.L., Gupta A., et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006, 4. CD004175.
97. Lau A.C., Duong T.T., Ito S., et al. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009, 60(7):2131-2141.
98. Saphyakhajon P., Greene G.R. Do we need high-dose acetylsalicylic acid (ASA) in Kawasaki disease?. J Pediatr 1998, 133(1):167.
99. Durongpisitkul K., Soongswang J., Laohaprasitiporn D., et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003, 24(2):145-148.
100. Tremoulet A.H., Best B.M., Song S., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008, 153(1):117-121.
101. Burns J.C., Capparelli E.V., Brown J.A., et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998, 17(12):1144-1148.
102. Fong N.C., Hui Y.W., Li C.K., et al. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 2004, 25(1):31-34.
103. Muta H., Ishii M., Egami K., et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004, 144(4):496-499.
104. Sundel R.P., Burns J.C., Baker A., et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993, 123(4):657-659.
105. Newburger J.W. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999, 135(4):411-413.
106. Sleeper L.A., Minich L.L., McCrindle B.M., et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011, 158:831-835.
107. Sano T., Kurotobi S., Matsuzaki K., et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007, 166(2):131-137.
108. Fukunishi M., Kikkawa M., Hamana K., et al. Prediction of non-responsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000, 137(2):172-176.
109. Freeman A.F., Shulman S.T. Refractory Kawasaki disease. Pediatr Infect Dis J 2004, 23(5):463-464.
110. Han R.K., Silverman E.D., Newman A., et al. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000, 154(7):694-699.
111. Kato H., Koike S., Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979, 63(2):175-179.
112. Shulman S.T. Is there a role for corticosteroids in Kawasaki disease?. J Pediatr 2003, 142(6):601-603.
113. Wright D.A., Newburger J.W., Baker A., et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128(1):146-149.
114. Hashino K., Ishii M., Iemura M., et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43(3):211-217.
115. Lang B.A., Yeung R.S., Oen K.G., et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006, 33(4):803-809.
116. Ogata S., Bando Y., Kimura S., et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009, 53(1):15-19.
117. Adachi S., Sakaguchi H., Kuwahara T., et al. High regression rate of coronary aneurysms developed in patients with immune globulin-resistant Kawasaki disease treated with steroid pulse therapy. Tohoku J Exp Med 2010, 220(4):285-290.
118. Millar K., Manlhiot C., Yeung R.S., et al. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int J Cardiol 2012, 154(1):9-13.
119. Wooditch A.C., Aronoff S.C. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics 2005, 116(4):989-995.
120. Burns J.C., Best B.M., Mejias A., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153(6):833-838.
121. Matsubara T., Furukawa S., Yabuta K., et al. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 56(1):29-36.
122. Suzuki H., Terai M., Hamada H., et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011, 30(10):871-876.
123. Portman M.A., Olson A., Soriano B., et al. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011, 161(3):494-499.
124. Weiss J.E., Eberhard B.A., Chowdhury D., et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004, 31(4):808-810.
125. Stenbøg E.V., Windelborg B., Hørlyck A., et al. The effect of TNFα blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol 2006, 35(4):318-321.
126. Burns J.C., Mason W.H., Hauger S.B., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146(5):662-667.
127. Raman V., Kim J., Sharkey A., et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporine A therapy. Pediatr Infect Dis J 2001, 20(6):635-637.
128. Ahn S.Y., Kim D.S. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005, 34(2):136-139.
129. Wallace C.A., French J.W., Kahn S.J., et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000, 105:e78.
130. Inoue Y., Okada Y., Shinohara M., et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006, 149(3):336-341.
131. Newburger J.W., Sleeper L.A., McCrindle B.W., et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356(7):663-675.
132. McCrindle B.W. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation 2009, 120:6-8.
133. Dhillon R., Clarkson P., Donald A.E., et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996, 94:2103-2106.
134. Kavey R.E., Allada V., Daniels S.R., et al. Cardiovascular risk reduction in high-risk pediatric patients. Circulation 2006, 114:2710-2738.
135. Kato H., Ichinose E., Yoshioka F., et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982, 49:1758-1766.
136. Sugimura T., Kato H., Inoue O., et al. Intravascular ultrasound of coronary arteries in children. Circulation 1994, 89:258-265.
137. Yamakawa R., Ishii M., Sugimura T., et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998, 31:1074-1080.
138. Fukushige J., Takahashi N., Ueda K., et al. Long-term outcome of coronary abnormalities in patients after Kawasaki disease. Pediatr Cardiol 1996, 17:71-76.
139. Gidding S.S. Late onset valvular dysfunction in Kawasaki disease. Prog Clin Biol Res 1987, 250:305-309.